{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:39:19Z","timestamp":1789609159918,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T00:00:00Z","timestamp":1629676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T00:00:00Z","timestamp":1629676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s10072-021-05561-z","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T02:02:42Z","timestamp":1629684162000},"page":"2031-2041","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience"],"prefix":"10.1007","volume":"43","author":[{"given":"Luca","family":"Diamanti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Picca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Bini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Gastaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Alfonsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pichiecchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Rota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Rud\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Villani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edvina","family":"Gali\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Vogrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariarosaria","family":"Valente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Zoccarato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Poretto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Giometto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Cimminiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Del Vecchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Marchioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,23]]},"reference":[{"key":"5561_CR1","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359:1350\u20131355. https:\/\/doi.org\/10.1126\/science.aar4060","journal-title":"Science"},{"key":"5561_CR2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158\u2013168. https:\/\/doi.org\/10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"5561_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","volume":"44","author":"L Spain","year":"2016","unstructured":"Spain L, Diem S, Larkin J (2016) Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44:51\u201360. https:\/\/doi.org\/10.1016\/j.ctrv.2016.02.001","journal-title":"Cancer Treat Rev"},{"key":"5561_CR4","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1097\/CCO.0000000000000681","volume":"32","author":"B Berzero","year":"2020","unstructured":"Berzero B, Picca A, Psimaras D (2020) Neurological complications of chimeric antigen receptor T cells and immune-checkpoint inhibitors: ongoing challenges in daily practice. Curr Opin Oncol 32:603\u2013612. https:\/\/doi.org\/10.1097\/CCO.0000000000000681","journal-title":"Curr Opin Oncol"},{"key":"5561_CR5","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1097\/WCO.0000000000000503","volume":"30","author":"M Touat","year":"2017","unstructured":"Touat M, Talmasov D, Ricard D et al (2017) Neurological toxicities associated with immune-checkpoint inhibitors. Curr Opin Neurol 30:659\u2013668. https:\/\/doi.org\/10.1097\/WCO.0000000000000503","journal-title":"Curr Opin Neurol"},{"key":"5561_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","volume":"73","author":"S Cuzzubbo","year":"2017","unstructured":"Cuzzubbo S, Javeri F, Tissier M et al (2017) Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer 73:1\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2016.12.001","journal-title":"Eur J Cancer"},{"key":"5561_CR7","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","volume":"7","author":"DB Johnson","year":"2019","unstructured":"Johnson DB, Manouchehri A, Haugh AM et al (2019) Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer 7:134. https:\/\/doi.org\/10.1186\/s40425-019-0617-x","journal-title":"J Immunother Cancer"},{"key":"5561_CR8","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/neuonc\/nou001","volume":"16","author":"B Liao","year":"2014","unstructured":"Liao B, Shroff S, Kamiya-Matsuoka C et al (2014) Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro-Oncol 16:589\u2013593. https:\/\/doi.org\/10.1093\/neuonc\/nou001","journal-title":"Neuro-Oncol"},{"key":"5561_CR9","doi-asserted-by":"publisher","first-page":"e985","DOI":"10.1212\/WNL.0000000000006124","volume":"91","author":"M Touat","year":"2018","unstructured":"Touat M, Maisonobe T, Knauss S et al (2018) Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology 91:e985\u2013e994. https:\/\/doi.org\/10.1212\/WNL.0000000000006124","journal-title":"Neurology"},{"key":"5561_CR10","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1212\/WNL.0000000000007235","volume":"92","author":"A Johansen","year":"2019","unstructured":"Johansen A, Christensen SJ, Scheie D et al (2019) Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: systematic review. Neurology 92:663\u2013674. https:\/\/doi.org\/10.1212\/WNL.0000000000007235","journal-title":"Neurology"},{"key":"5561_CR11","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","volume":"89","author":"S Suzuki","year":"2017","unstructured":"Suzuki S, Ishikawa N, Konoeda F et al (2017) Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89:1127\u20131134. https:\/\/doi.org\/10.1212\/WNL.0000000000004359","journal-title":"Neurology"},{"key":"5561_CR12","doi-asserted-by":"publisher","first-page":"e002890","DOI":"10.1136\/jitc-2021-002890","volume":"9","author":"AC Guidon","year":"2021","unstructured":"Guidon AC, Burton LB, Chwalisz BK et al (2021) Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer 9:e002890. https:\/\/doi.org\/10.1136\/jitc-2021-002890","journal-title":"J Immunother Cancer"},{"key":"5561_CR13","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"JBAG Haanen","year":"2017","unstructured":"Haanen JBAG, Carbonnel F, Robert C et al (2017) Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv119-42. https:\/\/doi.org\/10.1093\/annonc\/mdx225","journal-title":"Ann Oncol"},{"key":"5561_CR14","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36:1714\u20131768. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"5561_CR15","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.3389\/fneur.2019.01385","volume":"10","author":"M Gastaldi","year":"2019","unstructured":"Gastaldi M, Zardini E, Scaranzin S et al (2019) Autoantibody diagnostics in neuroimmunology: experience from the 2018 Italian neuroimmunology association external quality assessment program. Front Neurol 10:1385. https:\/\/doi.org\/10.3389\/fneur.2019.01385","journal-title":"Front Neurol"},{"key":"5561_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ensci.2018.11.023","volume":"14","author":"E Rota","year":"2019","unstructured":"Rota E, Varese P, Agosti S et al (2019) Concomitant myasthenia gravis, myositis, myocarditis and polyneuropathy, induced by immune-checkpoint inhibitors: a life-threatening continuum of neuromuscular and cardiac toxicity. eNeurological Sci 14:4\u20135. https:\/\/doi.org\/10.1016\/j.ensci.2018.11.023","journal-title":"eNeurological Sci"},{"key":"5561_CR17","doi-asserted-by":"publisher","first-page":"669493","DOI":"10.3389\/fneur.2021.669493","volume":"12","author":"F Bruno","year":"2021","unstructured":"Bruno F, Palmiero RA, Ferrero B et al (2021) Pembrolizumab-induced isolated cranial neuropathy: a rare case report and review of literature. Front Neurol 12:669493. https:\/\/doi.org\/10.3389\/fneur.2021.669493","journal-title":"Front Neurol"},{"issue":"P4","key":"5561_CR18","first-page":"2","volume":"92","author":"V Poretto","year":"2019","unstructured":"Poretto V, Buganza M, Filipponi S et al (2019) Hunting the real culprit: a complex case of nivolumab-related myelitis. (P4.2\u2013006). Neurology 92(P4):2\u2013006","journal-title":"Neurology"},{"key":"5561_CR19","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/ana.25708","volume":"87","author":"D Dubey","year":"2020","unstructured":"Dubey D, David WS, Reynolds KL et al (2020) Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum. Ann Neurol 87:659\u2013669. https:\/\/doi.org\/10.1002\/ana.25708","journal-title":"Ann Neurol"},{"key":"5561_CR20","doi-asserted-by":"publisher","first-page":"fcaa181","DOI":"10.1093\/braincomms\/fcaa181","volume":"2","author":"S Shelly","year":"2020","unstructured":"Shelly S, Triplett JD, Pinto MV et al (2020) Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy. Brain Commun 2:fcaa181. https:\/\/doi.org\/10.1093\/braincomms\/fcaa181","journal-title":"Brain Commun"},{"key":"5561_CR21","doi-asserted-by":"publisher","first-page":"e2442","DOI":"10.1212\/WNL.0000000000010632","volume":"95","author":"E Sechi","year":"2020","unstructured":"Sechi E, Markovic SN, McKeon A et al (2020) Neurological autoimmunity and immune checkpoint inhibitors: autoantibody profiles and outcomes. Neurology 95:e2442\u2013e2452. https:\/\/doi.org\/10.1212\/WNL.0000000000010632","journal-title":"Neurology"},{"key":"5561_CR22","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","volume":"96","author":"A Marini","year":"2021","unstructured":"Marini A, Bernardini A, Gigli GL et al (2021) Neurologic adverse events of immune checkpoint inhibitors: a systematic review. Neurology 96:754\u2013766. https:\/\/doi.org\/10.1212\/WNL.0000000000011795","journal-title":"Neurology"},{"key":"5561_CR23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/jns.12371","volume":"25","author":"J Bruna","year":"2020","unstructured":"Bruna J, Argyriou AA, Anastopoulou GG et al (2020) Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: experience beyond the clinical trials. J Peripher Nerv Syst 25:171\u2013177. https:\/\/doi.org\/10.1111\/jns.12371","journal-title":"J Peripher Nerv Syst"},{"key":"5561_CR24","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1007\/s12094-019-02060-8","volume":"21","author":"CR Garcia","year":"2019","unstructured":"Garcia CR, Jayswal R, Adams V et al (2019) Multiple sclerosis outcomes after cancer immunotherapy. Clin Transl Oncol 21:1336\u20131342. https:\/\/doi.org\/10.1007\/s12094-019-02060-8","journal-title":"Clin Transl Oncol"},{"key":"5561_CR25","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.annonc.2020.03.285","volume":"31","author":"J Haanen","year":"2020","unstructured":"Haanen J, Ernstoff MS, Wang Y et al (2020) Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. Ann Oncol 31:724\u2013744. https:\/\/doi.org\/10.1016\/j.annonc.2020.03.285","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"5561_CR26","doi-asserted-by":"publisher","first-page":"S74","DOI":"10.1111\/jns.12339","volume":"24","author":"D Psimaras","year":"2019","unstructured":"Psimaras D (2019) Immune checkpoint inhibitors-induced neuromuscular toxicity: from pathogenesis to treatment. J Peripher Nerv Syst 24(Suppl 2):S74-85. https:\/\/doi.org\/10.1111\/jns.12339","journal-title":"J Peripher Nerv Syst"},{"key":"5561_CR27","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/CJI.0000000000000278","volume":"42","author":"O Becquart","year":"2019","unstructured":"Becquart O, Lacotte J, Malissart P et al (2019) Myasthenia gravis induced by immune checkpoint inhibitors. J Immunother 42:309\u2013312. https:\/\/doi.org\/10.1097\/CJI.0000000000000278","journal-title":"J Immunother"},{"key":"5561_CR28","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12883-019-1416-1","volume":"19","author":"H Kamo","year":"2019","unstructured":"Kamo H, Hatano T, Kanai K et al (2019) Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report. BMC Neurol 19:184. https:\/\/doi.org\/10.1186\/s12883-019-1416-1","journal-title":"BMC Neurol"},{"key":"5561_CR29","doi-asserted-by":"publisher","first-page":"102455","DOI":"10.1016\/j.autrev.2019.102455","volume":"19","author":"A Matas-Garc\u00eda","year":"2020","unstructured":"Matas-Garc\u00eda A, Milisenda JC, Selva-O\u2019Callaghan A et al (2020) Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern. Autoimmun Rev 19:102455. https:\/\/doi.org\/10.1016\/j.autrev.2019.102455","journal-title":"Autoimmun Rev"},{"key":"5561_CR30","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1136\/annrheumdis-2018-213777","volume":"78","author":"AL Mammen","year":"2019","unstructured":"Mammen AL, Rajan A, Pak K et al (2019) Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1. Ann Rheum Dis 78:150\u2013152. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213777","journal-title":"Ann Rheum Dis"},{"key":"5561_CR31","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jaut.2019.03.005","volume":"100","author":"M Seki","year":"2019","unstructured":"Seki M, Uruha A, Ohnuki Y et al (2019) Inflammatory myopathy associated with PD-1 inhibitors. J Autoimmun 100:105\u2013113. https:\/\/doi.org\/10.1016\/j.jaut.2019.03.005","journal-title":"J Autoimmun"},{"key":"5561_CR32","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi JJ, Salem J-E, Sosman JA et al (2018) Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 391:933. https:\/\/doi.org\/10.1016\/S0140-6736(18)30533-6","journal-title":"Lancet"},{"key":"5561_CR33","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMc1901677","volume":"380","author":"J-E Salem","year":"2019","unstructured":"Salem J-E, Allenbach Y, Vozy A et al (2019) Abatacept for severe immune checkpoint inhibitor\u2013associated myocarditis. N Engl J Med 380:2377\u20132379. https:\/\/doi.org\/10.1056\/NEJMc1901677","journal-title":"N Engl J Med"},{"key":"5561_CR34","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1634\/theoncologist.2017-0344","volume":"23","author":"KP Papadopoulos","year":"2018","unstructured":"Papadopoulos KP, Romero RS, Gonzalez G et al (2018) Anti-hu-associated autoimmune limbic encephalitis in a patient with PD-1 inhibitor-responsive myxoid chondrosarcoma. Oncologist 23:118\u2013120. https:\/\/doi.org\/10.1634\/theoncologist.2017-0344","journal-title":"Oncologist"},{"key":"5561_CR35","doi-asserted-by":"publisher","first-page":"576980","DOI":"10.1016\/j.jneuroim.2019.576980","volume":"334","author":"A Gill","year":"2019","unstructured":"Gill A, Perez MA, Perrone CM et al (2019) A case series of PD-1 inhibitor-associated paraneoplastic neurologic syndromes. J Neuroimmunol 334:576980. https:\/\/doi.org\/10.1016\/j.jneuroim.2019.576980","journal-title":"J Neuroimmunol"},{"key":"5561_CR36","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1093\/jjco\/hyw090","volume":"46","author":"R Tanaka","year":"2016","unstructured":"Tanaka R, Maruyama H, Tomidokoro Y et al (2016) Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barr\u00e9 syndrome: a case report. Jpn J Clin Oncol 46:875\u2013878. https:\/\/doi.org\/10.1093\/jjco\/hyw090","journal-title":"Jpn J Clin Oncol"},{"key":"5561_CR37","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","volume":"5","author":"A Simonaggio","year":"2019","unstructured":"Simonaggio A, Michot JM, Voisin AL et al (2019) Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncol 5:1310\u20131317. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1022","journal-title":"JAMA Oncol"},{"key":"5561_CR38","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ejca.2017.05.036","volume":"83","author":"W Boisseau","year":"2017","unstructured":"Boisseau W, Touat M, Berzero G et al (2017) Safety of treatment with nivolumab after ipilimumab-related meningoradiculitis and bilateral optic neuropathy. Eur J Cancer 83:28\u201331. https:\/\/doi.org\/10.1016\/j.ejca.2017.05.036","journal-title":"Eur J Cancer"},{"key":"5561_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214336","volume":"78","author":"J Delyon","year":"2019","unstructured":"Delyon J, Brunet-Possenti F, Leonard-Louis S et al (2019) Immune checkpoint inhibitor rechallenge in patients with immune-related myositis. Ann Rheum Dis 78:e129. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214336","journal-title":"Ann Rheum Dis"},{"key":"5561_CR40","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","volume":"6","author":"C Dolladille","year":"2020","unstructured":"Dolladille C, Ederhy S, Sassier M et al (2020) Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol 6:865\u2013871. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0726","journal-title":"JAMA Oncol"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05561-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-021-05561-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05561-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T06:35:54Z","timestamp":1645425354000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-021-05561-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,23]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["5561"],"URL":"https:\/\/doi.org\/10.1007\/s10072-021-05561-z","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,23]]},"assertion":[{"value":"6 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The retrospective study was approved by institutional ethic committee (No. 20190026431).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was waived for de-identified, retrospective data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}